1. Generics Bulletin
  2. >>Business
  3. >>Deals

Beximco Completes Acquisition Of Sanofi Bangladesh

Company Takes Majority Stake In Sanofi Bangladesh For Just Over $50m

 
• By Akriti Seth

Beximco has completed its acquisition of a majority stake in Sanofi Bangladesh to “expand its core capabilities and product offerings.” With its second major acquisition under its belt, Beximco said that it plans to continue its diversification and expansion.

Acquisition
Beximco completes its second major acquisition with Sanofi Bangladesh • Source: Alamy

Bangladesh-based Beximco has announced completing the acquisition of a majority stake in Sanofi Bangladesh for £39.35m ($53.59m). According to Beximco, the deal is in line with its strategy to expand core capabilities and product offerings.

“We have a clear strategy to continue our diversification and expansion while strengthening our position as a market-leading pharma company in Bangladesh,” said Nazmul Hassan, managing director of Beximco

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

More from Business